CAP Flashcards

1
Q

What is pneumonia?

A
  • Lower respiratory tract infection
  • Infection of lung parenchyma
  • Proliferation of microbial pathogens in alveolar level
  • Most common is bacterial pneumonia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the 3 mechanisms for pathogenesis of pneumonia?

A
  1. Aspiration of oropharyngeal secretions
  2. Inhalation of aerosols
  3. Hematogenous spreading
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Signs and symptoms of pneumonia?

A

Pulmonary symptoms: cough, chest pain, shortness of breath, hypoxia

Systemic signs and symptoms: fever > 38, chills, tachypnea, tachycardia, hypotension, leukocytosis (elevated whites)

Elderly often present with symptoms that are more subtle and non specific, e.g. fatigue, anorexia, nausea, changes in mental status

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Physical examination of pneumonia?

A
  • Diminished breath sounds over affected area

- Inspiratory crackles during lung expansion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Radio graphic findings for pneumonia?

A
  • chest x ray or CT scan

- look for new infiltrates or dense consolidations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Respiratory cultures for pneumonia?

A

Sputum cultures are of low yield -> frequent contamination by oropharyngeal secretions

Lower respiratory tract samples

  • less contamination
  • invasive sampling, e.g. BAL (bronchoalveolar lavage)

Blood culture
- to rule out bacteremia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the classifications of pneumonia?

A
  • Community Acquired Pneumonia (CAP) - onset in community or <48h after hospital admission
  • Hospital Acquired Pneumonia (HAP) - onset at least 48h after hospital admission
  • Ventilator Associated Pneumonia (VAP) - onset at least 48h after mechanical ventilation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Risk factors for CAP?

A
  • Age of 65 years or more
  • Previous hospitalisation for CAP
  • Smoking
  • COPD,DM,HF,cancer,immunosuppression
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Prevention strategies for CAP?

A
  • smoking cessation

- immunisation (influenza, pneumococcal)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Microbiology for CAP?

A

For outpatient:

  • streptococcus pneumoniae
  • haemophilus influenzae
  • atypical organisms, e.g. mycoplasma pneumoniae, chlamydophila pneumoniae

Inpatient (non-severe):

  • streptococcus pneumoniae
  • haemophilus influenzae
  • atypical - mycoplasma pneumoniae, chlamydophila pneumoniae, Legionella pneumophilia

Inpatient (severe):

  • streptococcus pneumoniae
  • haemophilus influenzae
  • atypical - mycoplasma pneumoniae, chlamydophila pneumoniae, Legionella pneumophilia
  • staphylococcus aureus
  • other gram neg bacilli e.g. klebsiella pneumonia, Burkholderia pseudomallei
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are some tools for risk stratification for CAP?

A
  • Pneumonia Severity Index (PSI)

- CURB-65 score

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Criteria for SEVERE CAP?

A

2 Major criteria:

Mechanical ventilation

Septic shock requiring vasoactive medications

8 Minor criteria:

RR ≥ 30 breaths/min

PaO /FiO ≤ 250

Multilobar infiltrates

Confusion/disorientation

Uremia (urea > 7 mmol/L)

Leukopenia (WBC < 4 x 109/L)

Hypothermia (core temperature < 360C)

Hypotension requiring aggressive fluid resuscitation

Severe CAP: 1 or more major criterion OR 3 or more minor criteria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

For outpatient CAP, generally healthy patients, what is the standard regimen?

A

PO Beta lactam (amoxicillin) 1g PO TDS

OR

PO Respiratory FQ (levofloxacin 750mg PO OD or moxifloxacin) *USED IN PATIENTS WITH SEVERE PENICILLIN ALLERGY

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

For outpatient CAP, if there is Chronic heart, lung, liver or renal diseases, diabetes mellitus, alcoholism, malignancy, asplenia, what would the standard regimen be?

A

PO Beta Lactam (amoxicillin/clavulanate 625mg PO TDS or 2g PO BD; or cefuroxime 500mg PO BD)
+ PO Macrolide (clarithromycin 500mg PO BD or azithromycin 500mg PO OD);
OR Doxycycline 100mg PO BD (to cover atypical)

OR 
Respiratory FQ (levofloxacin 750mg PO OD or moxifloxacin) (if pt has severe beta lactam allergy)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Standard regimen for NON-SEVERE INPATIENT?

A

IV Beta lactam (amoxicillin/clavulanate 1.2g IV Q8H OR ceftriaxone 1-2g IV Q24H)
+ PO Macrolide (clarithromycin 500mg PO BD or azithromycin 500mg PO OD) OR PO doxycycline 100mg PO BD —> for atypical coverage

OR

IV Respiratory FQ (levofloxacin 750mg IV Q24H or moxifloxacin) (for severe beta lactam allergy)

If cannot tolerate PO Macrolide or doxycycline, use IV Azithromycin 500mg IV Q24H or IV Clarithromycin 500mg IV Q12H
Step down from IV to PO later

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Standard regimen for SEVERE INPATIENT?

A

IV Beta lactam (IV amoxicillin/clavulanate 1.2g IV Q8H PLUS IV ceftazidime 2g IV Q8H for burkholderia coverage)
PLUS
PO Macrolide (clarithromycin 500mg PO BD 500mg IV Q12H or azithromycin 500mg PO OD 500mg IV Q24H) OR PO doxycycline 100mg PO BD (for atypical coverage)

OR
IV Respiratory FQ (levofloxacin 750mg IV Q24H or moxifloxacin)
PLUS IV ceftazidime for burkholderia coverage

If there is severe penicillin allergy, then don’t use ceftazidime. Just use respiratory FQ even though not covering 2g IV Q8H for Burkholderia.

17
Q

When do we provide anaerobic coverage for inpatient CAP?

A

Any ONE of the following

  • Lung abscess
  • Empyema
18
Q

What to use for anaerobic coverage for inpatients?

A

ADD if standard regimen has NO anaerobic activity:

  • Clindamycin IV/PO
  • Metronidazole IV/PO

Amoxicillin/clavulanate and moxifloxacin have anaerobic coverage -> no action needed.

19
Q

When do we provide MRSA coverage for inpatients?

A

Any ONE of the following

  • Prior respiratory isolation of MRSA in last 1 year
  • Severe CAP only: hospitalization and received IV antibiotics within last 90 days (and locally validated risk factors)
20
Q

How to provide MRSA coverage for inpatients?

A

ADD to standard regimen:

IV Vancomycin OR
IV/PO Linezolid

21
Q

When do we provide pseudomonal coverage for inpatients?

A

Prior respiratory isolation of Pseudomonas aeruginosa in last 1 year

22
Q

How do we provide pseudomonal coverage for NON- SEVERE inpatients?

A

Modify regimen:
Beta lactam (IV Pip/tazo)
PLUS
Macrolide (clarithromycin or azithromycin) or doxycycline

OR 
Respiratory FQ (levofloxacin) AND NOT moxifloxacin bc it does not cover pseudomonas.
23
Q

Why are respiratory FQ not used as first line therapy for CAP?

A
  • Many adverse effects
  • Development of resistance with overuse (i.e. collateral damage)

– Preserve activity for other Gram‐negative infections
• Levofloxacin (and ciprofloxacin)

  • Alternative Pseudomonas coverage with severe penicillin allergies; Only PO options covering Pseudomonas aeruginosa
    – Delay diagnosis of tuberculosis
24
Q

Is adjunctive corticosteroid therapy recommended?

A

Reduces inflammation in the lungs
May decrease length of stay and time to clinical stability
However, any impact is small and likely outweighed by increased hyperglycemia
hence, NOT routinely recommended.

25
Q

How to monitor efficacy of therapy?

A

Clinical improvement expected in 48-72 hours.
• ↓ Cough, chest pain, shortness of breath, fever, WBC, tachypnea, etc.
• Elderly patients and/or those with multiple co‐morbidities may take longer

Should not escalate abx therapy in first 72H, unless culture directed or significant clinical deterioration.

Radiographic improvement lags behind clinical improvement.

26
Q

When can we stop empiric coverage for MRSA or pseudomonas?

A

May be stopped in 48H if no MRSA or pseudomonas us found on culture and patient is improving.

27
Q

When can we step down from IV to PO therapy?

A

If ALL 5 of the following criteria are met:
Hemodynamically stable
Clinically improved/improving
Afebrile ≥ 24 hours
Normally functioning gastrointestinal tract
Able to ingest PO medications

28
Q

What are the benefits of IV to PO?

A
  • greater patient comfort and mobility
  • reduced risk of nosocomial acquired bloodstream infections
  • decreased phlebitis
  • decreased preparation and administration time
  • reduced costs (drug, IV tubing, syringes, time)
  • facilitates discharge
29
Q

What oral abx do we use for step down therapy?

A

Positive cultures:
Use susceptibility results to guide selection of PO abx

No positive cultures:
Use either same antibiotic if available both IV and PO or another antibiotic from the same class

30
Q

Treatment duration for CAP?

A

Until clinical stability is achieved AND for at least 5 days.

Most achieve clinical stability in 48-72H, but still need at least a 5 day course.

Clinical stability: Afebrile, able to maintain oral intake, normal vital signs, oxygen saturation and mental status

Exception: MRSA & Pseudononas - 7 days
Burkholderia: 3-6 months